ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005148

type 2 diabetes mellitus

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. type 2 diabetes mellitus. Diseases, record MONDO_0005148. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005148

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
type 2 diabetes mellitus
Open Targets
Open Targets ID
MONDO_0005148
Open Targets
Other names
Adult-Onset Diabetes Mellitus, DIABETES MELLITUS TYPE 02, Diabetes Mellitus, Adult Onset, Diabetes Mellitus, Ketosis Resistant, Diabetes Mellitus, Maturity Onset, Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Noninsulin Dependent, Diabetes Mellitus, Slow Onset, Diabetes Mellitus, Stable, Ketosis-Resistant Diabetes Mellitus, MODY, Maturity Onset Diabetes Mellitus, NIDDM, Slow-Onset Diabetes Mellitus, Stable Diabetes Mellitus, T2D, T2DM, T2DM - type 2 diabetes mellitus, adult onset diabetes, diabetes mellitis type 2, diabetes mellitis type II, diabetes mellitus type 2, diabetes mellitus, noninsulin-dependent, association with, diabetes mellitus, noninsulin-dependent, late onset, diabetes mellitus, type II, diabetes, type 2, insulin resistance, severe, digenic, non-insulin dependent diabetes, non-insulin dependent diabetes mellitus, noninsulin dependent diabetes, noninsulin-dependent diabetes mellitus, type 2 diabetes, type 2 diabetes mellitus non-insulin dependent, type II diabetes, type II diabetes mellitus
Open Targets
Disease Ontology
DOID:9352
Disease Ontology
MeSH
D003924
MeSH
NCI Thesaurus
C26747
NCI Thesaurus
Highest stage of its drugs
Approval, for 70 of its 613 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs613

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
METFORMINCHEMBL1431Small moleculeApprovalEMA Human Drugs and TTD549525523Drugs and targets
SITAGLIPTINCHEMBL1422Small moleculeApprovalEMA Human Drugs and TTD277262261Drugs and targets
INSULIN GLARGINECHEMBL1201497ProteinApprovalDailyMed, EMA Human Drugs and PMDA270260254Drugs and targets
INSULIN HUMANCHEMBL1201631ProteinApprovalDailyMed258253226Drugs and targets
LIRAGLUTIDECHEMBL4084119ProteinApprovalDailyMed, EMA Human Drugs, PMDA and TTD211201194Drugs and targets
SEMAGLUTIDECHEMBL2108724ProteinApprovalDailyMed, EMA Human Drugs, FDA, PMDA and TTD207200196Drugs and targets
DAPAGLIFLOZINCHEMBL429910Small moleculeApprovalEMA Human Drugs, FDA and TTD208198197Drugs and targets
EMPAGLIFLOZINCHEMBL2107830Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD176164164Drugs and targets
PIOGLITAZONECHEMBL595Small moleculeApprovalEMA Human Drugs and TTD184163161Drugs and targets
EXENATIDECHEMBL414357ProteinApprovalDailyMed, EMA Human Drugs, PMDA and TTD161151146Drugs and targets

1 to 10 of 613

See all 613 drugs

Targets333

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
PPARGPeroxisome proliferator-activated receptor23
Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma antagonist; Peroxisome proliferator-activated receptor gamma modulator; Peroxisome proliferator-activated receptor gamma partial agonist
Approvalhttps://conductscience.org/library/genes/5468Drugs and targets
DPP4Dipeptidyl peptidase 420Dipeptidyl peptidase IV inhibitorApprovalhttps://conductscience.org/library/genes/1803Drugs and targets
GLP1RGlucagon-like peptide 1 receptor17Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonistApprovalhttps://conductscience.org/library/genes/2740Drugs and targets
SLC5A2Sodium/glucose cotransporter 217Sodium/glucose cotransporter 2 inhibitorApprovalhttps://conductscience.org/library/genes/6524Drugs and targets
INSRInsulin receptor14Insulin receptor agonistApprovalhttps://conductscience.org/library/genes/3643Drugs and targets
PPARAPeroxisome proliferator-activated receptor14Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonistApprovalhttps://conductscience.org/library/genes/5465Drugs and targets
GCGRGlucagon receptor12Glucagon receptor agonist; Glucagon receptor antagonist; Glucagon receptor inhibitorPhase 3https://conductscience.org/library/genes/2642Drugs and targets
KCNJ11ATP-sensitive inward rectifier potassium channel 1112Potassium channel, inwardly rectifying, subfamily J, member 11 opener; Sulfonylurea receptor 1, Kir6.2 blockerApprovalhttps://conductscience.org/library/genes/3767Drugs and targets
ABCC8Sulfonylurea receptor 1, Kir6.211Sulfonylurea receptor 1, Kir6.2 blockerApprovalhttps://conductscience.org/library/genes/6833Drugs and targets
AGTR1Type-1 angiotensin II receptor11Type-1 angiotensin II receptor antagonistApprovalhttps://conductscience.org/library/genes/185Drugs and targets

1 to 10 of 333

See all 333 targets

Trials3,432

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 100 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT05162014To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin494,6792024-03-18Diabetes Mellitus, Type 2EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT05214573Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk386,3012025-10-10Type 2 Diabetes, Cardiac DiseaseDEXTROSEIts record names the diseaseClinicalTrials.gov
NCT02864914
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
333,5802024-11-15Diabetes Mellitus, Type 2EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT03817463A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes327,6242024-09-23Diabetes Mellitus, Type 2DEXTROSE, EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT05073692Comparison of Type 2 Diabetes Pharmacotherapy Regimens241,9812025-11-21Type 2 Diabetes Mellitus, Cardiovascular DiseasesEMPAGLIFLOZIN, EXENATIDE, GLIMEPIRIDE, GLIPIZIDE, LIRAGLUTIDEIts record names the diseaseClinicalTrials.gov
NCT02140645Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy166,6132017-02-08Diabetes Mellitus, Type 2LINAGLIPTINIts record names the diseaseClinicalTrials.gov
NCT05465317Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease62,1972024-09-19Diabetes Mellitus, Type 2EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT00659295Observational Study to Evaluate the Safety of Levemir® in Diabetes51,1702011-08-16Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2INSULIN DETEMIRIts record names the diseaseClinicalTrials.gov
NCT03050619Characteristics of Empagliflozin Initiators31,9082019-01-25Type 2 DiabetesDEXTROSE, EMPAGLIFLOZINIts record names the diseaseClinicalTrials.gov
NCT03993132A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes26,7742024-02-12Diabetes Mellitus, Type 2EMPAGLIFLOZIN, LIRAGLUTIDEIts record names the diseaseClinicalTrials.gov

1 to 10 of 3,432

See all 3,432 trials

Comparisons in its trials1,032

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Aims 1, 2B, and 3 Groups vs Aim 2A Group: deaths from any cause22,208 of 386,2760 of 25386,301NCT05214573Trial comparisons
Aims 1, 2B, and 3 Groups vs Aim 2A Group: serious adverse events40,642 of 386,2760 of 25386,301NCT05214573Trial comparisons
SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause1,371 of 163,8122,524 of 163,812327,624NCT03817463Trial comparisons
Empagliflozin Initiators vs Dipeptidyl Peptidate-4 Inhibitor (DPP4i) Initiators: deaths from any cause341 of 20,2791,528 of 41,91862,197NCT05465317Trial comparisons
Type 1 Diabetes vs Type 2 Diabetes: serious adverse events130 of 13,52980 of 37,64151,170NCT00659295Trial comparisons
Empagliflozin - PS Balanced Cohort vs Liraglutide - PS Balanced Cohort: deaths from any cause881 of 14,148765 of 12,62626,774NCT03993132Trial comparisons
Insulin Degludec vs Insulin Glargine: Occurrence of at Least One EAC Confirmed Severe Hypoglycaemic Episode Within a Subject (Yes/no)187 of 3,818252 of 3,8197,637NCT01959529Trial comparisons
Insulin Degludec vs Insulin Glargine: serious adverse events1,473 of 3,8181,517 of 3,8197,637NCT01959529Trial comparisons
Finerenone vs Placebo: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.350 of 3,686395 of 3,6667,352NCT02545049Trial comparisons
Finerenone vs Placebo: All-cause Hospitalization1,573 of 3,6861,605 of 3,6667,352NCT02545049Trial comparisons

1 to 10 of 1,032

See all 1,032 comparisons in its trials

Papers from its trials2,743

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
42251702RESULT1PubMed
42067440RESULT1PubMed
42010357RESULT1PubMed
41944220RESULT1PubMed
41928037RESULT1PubMed
41903163RESULT1PubMed
41778928RESULT1PubMed
41666927RESULT1PubMed
41406444RESULT1PubMed
41091469RESULT1PubMed

1 to 10 of 2,743

See all 2,743 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005148

GET https://conductscience.org/api/diseases/v1/MONDO_0005148/drugs?page=2

API referenceFor AI assistants